Replimune Group, Inc. (NASDAQ:REPL) Receives $16.80 Consensus Price Target from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has received a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $16.80.

REPL has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Tuesday, November 12th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in Replimune Group in the 1st quarter worth approximately $927,000. Jacobs Levy Equity Management Inc. purchased a new stake in Replimune Group in the 1st quarter worth approximately $1,088,000. Price T Rowe Associates Inc. MD lifted its position in Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after buying an additional 699,679 shares in the last quarter. Millennium Management LLC lifted its position in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after buying an additional 53,313 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of REPL opened at $10.80 on Tuesday. The firm has a market capitalization of $738.94 million, a PE ratio of -3.54 and a beta of 1.19. The company has a quick ratio of 13.46, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a 50-day moving average price of $11.46 and a 200 day moving average price of $9.57. Replimune Group has a 52-week low of $4.92 and a 52-week high of $12.97.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, sell-side analysts anticipate that Replimune Group will post -3.05 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.